AMP-Activated Protein Kinase Activation Leads to Lysome-Mediated NA⁺/I^ˉ-Symporter Protein Degradation in Rat Thyroid Cells

Abstract

Iodide uptake by thyroid cells is mediated by a transmembrane glycoprotein known as the Na⁺/I⁻-symporter (NIS). NIS-mediated iodide uptake plays important physiological role in thyroid gland function, as well as in diagnostic and treatment of Graves’ disease and thyroid cancer. Although different studies investigated the transcriptional mechanisms of NIS expression, there is no report on the NIS post-translational regulation related to NIS protein degradation in thyroid cells. Recently, our group showed that AMP-activated protein kinase (AMPK) plays a pivotal role in the rat thyroid gland, downregulating iodide uptake, NIS protein, and mRNA content. Since several studies demonstrated that AMPK regulates post-transcriptional mechanisms, such as autophagy-mediated processes in different tissues, we hypothesized that AMPK activation could also regulate NIS protein degradation through the lysosome pathway in thyroid cells. Rat follicular thyroid PCCL3 cells cultivated in Ham’s F12 supplemented with 5% calf serum and hormones were exposed to the AMPK pharmacological activator 5-aminoimidazole-4 carboxamide ribonucleoside (AICAR), in the presence or absence of Bafilomycin A1 or MG132 for 24 h. Treatment of PCCL3 cells with Bafilomycin A1 fully prevented the decrease of iodide uptake and NIS protein content mediated by AMPK activation. In contrast, the treatment with MG132 was unable to prevent the effects of AMPK activation on NIS. Our results show that AMPK activation significantly induces NIS protein degradation through a lysosome-mediated mechanism.

Key words

AMPK - Bafilomycin A1 - iodide uptake - NIS degradation

• References

• 1 Bizhanova A, Chop P. The Sodium-Iodide Symporter NIS and Pendrin in Iodide Homeostasis of the Thyroid. Endocrinology 2009; 150: 1084-1090
• 2 De la Vieja A, Dohan O, Levy O, Carrasco N. Molecular Analysis of the Sodium/Iodide Symporter: Impact on Thyroid and Extrathyroid Pathophysiology. Physiol Rev. 2000. 80. 1083-1105
• 3 Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ. Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001; 12: 1169-1175
• 4 Riedel C, Levy O, Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 2001; 276: 21458-21463
• 5 Andrade BM, Araujo RL, Perry RLS, Souza ECL, Cazarin JM, Carvalho DP, Ceddia RB. A novel role for AMP-kinase in the regulation of the Na⁺/I⁻ symporter and iodide uptake in the rat thyroid gland. Am J Physiol Cell Physiol 2011; 300: C1291-C1297
• 6 Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 2011; 25: 1895-1908
• 7 Andrade BM, Cazarin J, Zancan P, Carvalho DP. AMP-activated protein kinase upregulates glucose uptake in thyroid PCCL3 cells independent of thyrotropin. Thyroid 2012; 22: 1063-1068
• 8 Zhang Z, Beyer S, Jhiang SM. MEK inhibition leads to lysosome-mediated Na⁺/I⁻ symporter protein degradation in human breast cancer cells. Endocr Relat Cancer 2013; 20: 241-250
• 9 Abdulrahman R, Boon MR, Sips HC, Guigas BG, Rensen PC, Smit JW, Hovens GC. Impact of Metformin and Compound C on NIS expression and iodine uptake in vitro and in vivo: a role for CRE in AMPK modulation of thyroid function. Thyroid 2014; 24: 78-87
• 10 Weiss J, Philp NJ, Ambesi-Impiombato FS, Grollman EF. Thyrotropin-stimulated iodide transport mediated by adenosine 3′,5′-monophosphate and dependent on protein synthesis. Endocrinology 1984; 114: 1099-1107
• 11 Garcia B, Santisteban P. PI3K is involved in the IGF-1 inhibition of TSH-induced sodium/iodide symporter gene expression. J Endocrinol 2002; 16: 342-352
• 12 Zaballos MA, Garcia B, Santisteban P. Gβγ dimers released in response to thyrotropin activate phosphoinositide 3-kinase and regulate gene expression in thyroid cells. Mol Endocrinol 2008; 22: 1183-1199
• 13 Vadysirisack DD, Chen ESW, Zhang Z, Tsai MD, Chang GD, Jhiang SM. Identification of in Vivo Phosphorylation Sites and Their Functional Significance in the Sodium Iodide Symporter. J Biol Chem 2007; 282: 36820-36828
• 14 Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na⁺/I⁻ targeting to the membrane. Endocr Relat Cancer 2006; 13: 257-269
• 15 Lamy F, Taton M, Dumont JE, Roger PP. Control of protein synthesis by thyrotropin and epidermal growth factor in human thyrocytes: role of morphological changes. Mol Cell Endocrinol 1990; 73: 195-209
• 16 Hébrant A, van Staveren WC, Delys L, Solís DW, Bogdanova T, Andry G, Roger P, Dumont JE, Libert F, Maenhaut C. Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression. Exp Cell Res 2007; 313: 3276-3284
• 17 Choi HJ, Kim TY, Chung N, Yim JH, Kim WG, Kim JA, Kim WB, Shong YK. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside. J Endocrinol 2011; 211: 79-85
• 18 Vidal AP, Andrade BM, Vaisman F, Cazarin J, Pinto LF, Breitenbach MM, Corbo R, Caroli-Bottino A, Soares F, Vaisman M, Carvalho DP. AMP-activated protein kinase signaling is upregulated in papillary thyroid cancer. Eur J Endocrinol 2013; 169: 521-528